Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module A-D (Cert # L259161)

ACPE Numbers: Various – see listing below
Content Release Date: September 10, 2025
Expiration Dates: September 08, 2026
Activity Type: Application-based
CE Credits: 17 contact hours
Activity Fee: $315 (ASHP member); $455 (non-member)

The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The Home Study Syllabus is released as a single 17-hour package (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

Accreditation

Target Audience

These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:

Adult Acute Leukemia
Breast Cancer
Endometrial Cancer
Febrile Neutropenia
Gastroesophageal Cancers
Hematopoietic Cell Transplantation
Interpretation of late-phase oncology trials
Lymphomas
Multiple Myeloma
Oncology Practice Management
Pancreatic Cancer
Pharmacogenomics in Oncology
Prostate Cancer

Recertification Credit

Board-certified pharmacists are eligible to receive up to 17 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

BCOP recertification logo

ASHP and ACCP are approved by BPS as providers for the recertification of BCOP.

Learning Activity	ACPE Number	Contact Hours (ACPE & BPS)	Assessment Pass Point
Module A: Myeloma, Lymphoma, and Acute Leukemia	0204-9999-25-949-H01-P	4.0	78%
Module B: Oncology Practice Management, Endometrial Cancer, and Interpretation of Late-Phase Oncology Trials	0204-9999-25-950-H01-P	4.0	80%
Module C: Febrile Neutropenia; Pancreatic, Prostate, and Breast Cancers	0204-9999-25-951-H01-P	5.0	83%
Module D: Hematopoietic Cell Transplant, Gastric Cancer, and Pharmacogenomics	0204-9999-25-952-H01-P	4.0	80%

Articles and Learning Objectives

Module A: Myeloma, Lymphoma, and Acute Leukemia
ACPE # 0204-9999-25-949-H01-P

Silva W, Rego E. How to manage Philadelphia-positive acute lymphoblastic leukemia in resource-constrained settings. Cancers (Basel). 2023;15(24):5783.

Learning Objectives:

Develop recommendations for the management of Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in resource-constrained settings.
Select appropriate patients with Ph+ ALL to receive specific therapies based on genetic risk factors, according to clinical practice guidelines by Silva et al.

Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma. N Engl J Med. 2024;391(15):1379-1389.

Learning Objectives:

Describe the S1826 trial of nivolumab, doxorubicin, vinblastine, and dacarbazine (N+AVD) for the treatment of advanced-stage classic Hodgkin’s lymphoma.
Develop recommendations for the use of nivolumab, doxorubicin, vinblastine, and dacarbazine (N+AVD) for the treatment of advanced-stage classic Hodgkin’s lymphoma.

Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543-554.

Learning Objectives:

Develop recommendations for sequencing immunotherapies in the treatment of relapsed/refractory multiple myeloma based on the International Myeloma Working Group (IMWG) recommendations.
Describe the impact of conventional myeloma therapies on subsequent antimyeloma immunotherapy.
Select appropriate holding therapy and bridging therapy for patients receiving chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma based on IMWG recommendations.

Module B: Oncology Practice Management, Endometrial Cancer, and Interpretation of late-phase oncology trials
ACPE # 0204-9999-25-950-H01-P

Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024;42(3):283-299.

Learning Objectives:

Describe the study of durvalumab with or without olaparib in combination with chemotherapy for advanced or recurrent endometrial cancer.
Develop recommendations for the use of durvalumab with or without olaparib in combination with chemotherapy for patients with advanced or recurrent endometrial cancer.
Select appropriate patients to receive durvalumab with or without olaparib in combination with chemotherapy according to the results of DUO-E trial.

Chan A, Ng DQ, Arcos D, et al. Electronic patient-reported outcome-driven symptom management by oncology pharmacists in a majority-minority population: an implementation study. JCO Oncol Pract. 2024;20(12):1744-1754.

Learning Objectives:

Describe the methodology for obtaining patient recorded outcomes (PRO) in a pharmacist-led initiative for oncology patients.
Develop recommendations for the implementation of patient-specific education for patients who have submitted PRO data.
Select appropriate patients to collect PRO data and who can benefit from individualized pharmacist-led education for their antineoplastic treatment.

Lin TA, Sherry AD, Ludmir EB. Challenges, complexities, and considerations in the design and interpretation of late-phase oncology trials. Semin Radiat Oncol. 2023;33(4):429-437.

Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281.

Learning Objectives:

Describe study design challenges and complexities for late-phase oncology trials.
Interpret an oncology clinical trial evaluating darolutamide in combination with androgen-deprivation therapy for a patient with metastatic hormone-sensitive prostate cancer.
Select appropriate statistical methods for a late-phase oncology trial.

Module C: Febrile Neutropenia; Pancreatic, Prostate, and Breast Cancers
ACPE # 0204-9999-25-951-H01-P

Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor-2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2024;43(3):285-296.

Learning Objectives:

Describe the TROPION-Breast01 study of datopotamab deruxtecan for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer.
Develop recommendations for the use of datopotamab deruxtecan in patients with metastatic HR-positive, HER2-negative breast cancer.
Select appropriate patients to receive drug datopotamab deruxtecan based on the results of the TROPION-Breast01 trial.

Feng X, Qian C, Fan Y, et al. Is short-course antibiotic therapy suitable for Pseudomonas aeruginosa bloodstream infections in onco-hematology patients with febrile neutropenia? Results of a multi-institutional analysis. Clin Infect Dis. 2024;78(3):518-525.

Learning Objectives:

Describe the study of short-course antibiotic therapy for Pseudomonas aeruginosa bloodstream infections in malignant hematology patients with febrile neutropenia.
Develop recommendations for the use of short-course antibiotic therapy in neutropenic patients with Pseudomonas aeruginosa bloodstream infections.
Select appropriate patients to receive short-course antibiotic therapy based on the results of the study by Feng and colleagues.

Learning Objectives:

Describe the study of darolutamide and androgen deprivation therapy (ADT) for the treatment of prostate cancer in patients with metastatic castration-sensitive disease.
Select appropriate patients to receive darolutamide and ADT based on the results of the ARANOTE trial.
Develop recommendations for the use of darolutamide and ADT in patients with metastatic castration-sensitive prostate cancer.

Module D: Hematopoietic Cell Transplant, Gastric Cancer, and Pharmacogenomics
ACPE # 0204-9999-25-952-H01-P

Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766-1775.

Learning Objectives:

Describe the study of gilteritinib for post-transplant maintenance in acute myeloid leukemia.
Develop recommendations for the use of post-transplant maintenance gilteritinib in acute myeloid leukemia.
Select appropriate patients to receive post-transplant maintenance gilteritinib based on the results of the BMT CTN 1506/MORPHO trial.

Nichetti F, Rota S, Ambrosini P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer a systematic review and meta-analysis. JAMA Netw Open. 2024;7(1):e2350756.

Learning Objectives:

Describe the meta-analysis comparing NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer.
Develop recommendations for the use of NALIRIFOX, FOLFIRINOX, or gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer.
Select appropriate patients to receive NALIRIFOX, FOLFIRINOX, or gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer.

Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47-58.

Learning Objectives:

Describe the study of trastuzumab deruxtecan in patients with certain Her2-expressing solid tumors.
Develop recommendations for the use of trastuzumab deruxtecan in patients with Her2-expressing solid tumors.
Select appropriate patients with Her2 expression to receive trastuzumab deruxtecan based on the results of the DESTINY PanTumor02 phase II trial.

Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.

Learning Objectives:

Describe the GLOW trial comparing zolbetuximab and CAPOX to CAPOX alone as first-line chemotherapy for metastatic gastric and gastroesophageal cancers.
Develop recommendations for the use of zolbetuximab and CAPOX as first-line treatment for metastatic gastric and gastroesophageal cancers based on the GLOW trial.
Select appropriate patients to receive zolbetuximab and CAPOX based on the GLOW trial.

Faculty

Full Faculty Bios

Jessica Auten, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
University of North Carolina Medical Center
Chapel Hill, North Carolina

John Bossaer, PharmD, BCOP
Professor
ETSU Bill Gatton College of Pharmacy
Johnson City, Tennessee

*Courtney C. Cavalieri, PharmD, BCOP
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

*Karen M. Fancher, PharmD, BCOP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

Christopher Fausel, PharmD, MHA, BCOP
Director of Pharmacy Precision Genomics
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana

Lauren Ice, PharmD, BCOP, BCPS
Pharmacist Supervisor
Corewell Health
Grand Rapids, Michigan

Alexis R. Jones, PharmD, BCOP, CPP
Gynecologic Oncology Clinical Pharmacist
University of North Carolina Medical Center
Chapel Hill, North Carolina

Elyse A. MacDonald, PharmD, MS, BCPS, FASHP
Director, Investigational Drug Service
Stanford Health Care
Palo Alto, California

Donald C. Moore, PharmD, BCOP, BCPS, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Center
Charlotte, North Carolina

*Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Sherry L. Vogt, PharmD, BCOP
Clinical Specialist Pharmacist - Oncology
Hollings Cancer Center / Medical University of South Carolina
Charleston, South Carolina

*Christine M. Walko, PharmD, BCOP, FCCP
Senior Member, Individualized Cancer Management
Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida

Jennifer Young, PharmD, BCOP
Clinical Pharmacy Specialist
Cincinnati Children’s Hospital Medical Center Cinci
nnati, Ohio

*Content Matter Experts

Reviewers

Field Testers

Karen Abboud, PharmD, BCOP, BCPS
Nahla Ahmed, PharmD, BCOP
Judith Alberto, RPh, MHA, BCOP
Jonalyn Armitage, PharmD, BCOP
Kimberly Aronoff, BS Pharm, PharmD, BCOP
Chase Ayres, PharmD, BCOP
Christine Barrett, PharmD, BCOP
Allison Bass, PharmD, BCOP
Mollie Beck, PharmD, BCOP
Denae Beckman, PharmD, BCOP
Miranda Benfield, PharmD, BCOP
Lauren Blackwell, PharmD, BCOP
Chris Bohl, PharmD, BCOP
Janet Bramell, PharmD, BCOP, BCPS
Theresa Brown, PharmD, BCOP, CPP
Danielle Brown, PharmD, BCOP
Kimberley Campbell PharmD, BCOP
Melvi Chacko, PharmD, BCOP
Amanda Chan, PharmD, BCOP
Alexis Chapman, PharmD, BCOP
Anil Chava, PhD, MS, RPh, BCOP
Roy Choi, PharmD, BCACP, BCOP
Devon Coffey, PharmD, BCOP
Jill Comeau, PharmD, BCOP
Allison Cone, PharmD, BCPS, BCOP
Kori Costa, RPh, BCOP
Jessica Davis, PharmD, BCOP
Virginia Dickison, PharmD, BCPC, BCOP
Lindsey Douglass, PharmD, BCOP, BCPS
Sydney Elmore, PharmD, BCOP
Bryna Ewachiw, PharmD, BCOP
Zhou Fang, PharmD
Sara Fleszar, Pharm D, BCOP
Mei Ka Fong, PharmD, BCOP
Peter Gargano, PharmD, BCOP
Suzanne Gettys, PharmD, BCOP
Anna Gibson, PharmD, BCOP
Rene Gonzalez, PharmD, BCOP, BCPS
Benjamin Gruseck, PharmD, BCOP
David W Harris, PharmD, BCOP
Mikala Hillis, PharmD, MMHC, BCOP
Jerline Hsin, PharmD, BCPS, BCOP
Brooke Hueftle, PharmD, BCOP
Brooke Hueftle, PharmD, BCOP
Mitchell E. Hughes, PharmD, BCOP
Hyeree Jang, PharmD, BCOP, BCPS
Mark Jao, PharmD, BCOP
Behren Ketchum PharmD, BCOP
Divya Khandekar, PharmD, MS, BCOP
Abby Kim PharmD, BCOP
Audrey Kwon, PharmD, BCOP
Lesli Lavery, PharmD, BCOP
Carly Lee, PharmD, BCPS, BCOP
Jamie Lee, PharmD, BCOP
Vanessa Lehnhardt, PharmD, BCOP
Jaclyn Leland, PharmD, BCOP
Tanja Lepir, PharmD, BCOP
Michael Leung, PharmD, BCOP
Carin Lewis, PharmD, BCOP, BCPS
Linda Linderbeck, PharmD
Andrea Lippucci PharmD, BCOP, BCPS
Jonathan Malara, PharmD, BCOP
Izabela Mazur, PharmD, BCOP
Heather McCarthy, PharmD
William McSkimming, BS Pharm, PharmD, BCOP
Oxana Megherea, PharmD, BCOP
Mollie Michel, PharmD, BCOP
Grant Middendorff, PharmD, BCOP
Chukwuemeka Nzelibe, PharmD
Jooyoung Park, PharmD BCOP
Jolly Patel, PharmD, BCOP
Kinjal Patel, PharmD, BCOP
Puja Patel, PharmD, BCOP
Matthew Peery, PharmD, BCOP
Gloria Porcelli, BS Pharm , BCOP
Darla Quevedo, PharmD, BCOP
Morgan Randolph, PharmD, BCOP
Mohammad A. Rattu, PharmD, BCOP, BCPS, BCGP
Christine Read, PharmD, MS, BCOP
Forrest Ridgway, PharmD, BCOP, BCPS
Rebecca Riley, Pharm D, BCOP
Teresa Rushing, PharmD, BCOP, BCPS
Emily Rux, PharmD, BCOP
Kristen Rychalsky, PharmD, BCOP, BCPS
Stephanie Sanders, PharmD, BCCCP, BCOP
Deborah Sarama, PharmD, BCOP
Katherine Saunders PharmD, BCOP
Matthew Saylor, PharmD, BCOP
Sabrina Schneider, PharmD, BCOP
Nicole Scott, PharmD, BCOP
Patrick Shin, PharmD, BCOP, BCPS
Anna Shook, PharmD, BCPS, BCOP
Shayna Simon, PharmD, BCOP
Jeffrey Sivik, PharmD, BCOP
Joseph Sleeman, PharmD, BCOP
Ashley Stearns, PharmD, BCOP
Aaron Steele, PharmD, BCOP
Randolph Sturgill, PharmD, BCOP
Laura Sun, PharmD, BCOP
Quang Ta, PharmD, APh, BCPS, BCOP
Ming-Hei Tai, PharmD, BCOP
Lisa Thompson, PharmD, BCOP, CPPS
Krystal Titus-Rains, PharmD, BCOP, BCPS
James Toczylowski, PharmD, BCOP
Katelyn Toeniskoetter, PharmD, BCOP
Rebecca Tombleson, PharmD, BCOP
Meagan Wakefield, PharmD, BCOP
Christopher Wang, PharmD, BCOP
Chad Weber, PharmD, BCOP
Olivia White, PharmD, BCOP
Lily Yan, PharmD, BCOP
Olga Yankulina, PharmD, BCOP
David Yee, PharmD, BCOP
Barbara Yim, PharmD, BCOP
Amy Yim , PharmD, BCOP
Ephu Yip, PharmD, BCPS
Carolnn Yong, PharmD, BCOP, BCPS

Relevant Financial Relationship Disclosure

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

Jessica Auten: Advisory Board – Janssen
Courtney Cavalieri: Advisory Board – Pfizer
Karen Fancher: Advisory Board – AstraZeneca
Colleen McCabe: Speakers’ Bureau – BMS
Anthony Perissinotti: Consultant – AbbVie, Amgen, Servier
Danielle Roman: Advisor – Astellas, Daiichi Sankyo

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Development

Board Recert

Member

Non-Member

	The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
	The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Error